MMprofiler with SKY92 Combined with ISS to Identify Risk Status in Multiple Myeloma
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Gene expression profiling has been studied in the prognostication of multiple myeloma for over a decade, Usmani says. Now, different tools are making their way to the clinical setting, one of which is the MMprofiler.
Findings of the VTD arm of the phase III Gimema-MMY-3006 study were presented at the 2017 ASH Annual Meeting. This study investigated the MMprofiler with SKY92 combined with ISS to identify high- and low-risk patients with multiple myeloma.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
